Results 111 to 120 of about 16,072 (215)

Leishmania tarentolae as Potential Live Vaccine Co-Expressing Distinct Salivary Gland Proteins Against Experimental Cutaneous Leishmaniasis in BALB/c Mice Model. [PDF]

Front Immunol, 2022
Lajevardi MS, Gholami E, Taheri T, Sarvnaz H, Habibzadeh S, Seyed N, Mortazavi Y, Rafati S.   +7 more
europepmc   +1 more source

Immunopathology of Leishmaniasis: an update. [PDF]

, 2007
Leishmaniasis represents a severe, increasing, public health problem. The perspective of its control is highly dependent on research progress, on therapeutic manipulations of the immune system, and on vaccine development.
Cillari, E., DI LORENZO, G., Mansueto, P., Mansueto, S., Rini, G., Vitale, G.   +5 more
core   +1 more source

Improving reproducibility and translational potential of mouse models: lessons from studying leishmaniasis

Frontiers in Immunology
Leishmaniasis is a complex disease caused by protozoan parasites of the genus Leishmania, which are transmitted by phlebotomine sand flies. The clinical manifestations of leishmaniasis are diverse, ranging from self-healing cutaneous lesions to fatal ...
Mahmoud Nateghi-Rostami, Marie Lipoldová, Marie Lipoldová, Yahya Sohrabi, Yahya Sohrabi, Yahya Sohrabi   +5 more
doaj   +1 more source

Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.

PLoS Neglected Tropical Diseases, 2015
BackgroundThe only oral drug available for the treatment of leishmaniasis is miltefosine, described and approved for visceral leishmaniasis in India. Miltefosine is under evaluation for the treatment of cutaneous leishmaniasis in the Americas although ...
Juliana Q Reimão, Jordana C Oliveira, Cristiana T Trinconi, Paulo C Cotrim, Adriano C Coelho, Silvia R B Uliana   +5 more
doaj   +1 more source

MPLA and AddaVax^® Adjuvants Fail to Promote Intramuscular LaAg Vaccine Protectiveness against Experimental Cutaneous Leishmaniasis. [PDF]

Microorganisms, 2021
Oliveira-Maciel D, Dos-Santos JS, Oliveira-Silva G, Mello MF, da Fonseca-Martins AM, Carneiro MPD, Ramos TD, Firmino-Cruz L, Gomes DCO, Rossi-Bergmann B, de Matos Guedes HL.   +10 more
europepmc   +1 more source

Experiences with vaccines against cutaneous leishmaniasis: of men and mice [PDF]

, 2017
The need for a vaccine(s) against cutaneous leishmaniasis and the populations at risk for whom such vaccines should be developed are briefly discussed. The current human vaccine studies are reviewed, as are some experimental mouse studies with emphasis ...
Modabber, Farrokh
core  

The Effect(s) of Matricaria chamomilla on Leishmania major Ulcers in Balb/c Mice

Armaghane Danesh Bimonthly Journal, 2015
Background & aim: Treatment of cutaneous leishmaniasis (CL) is based on the use of pentavalent antimony compounds as injection drug with highly side effects.
AR Dashtpeima, AA Moshfe, L Manzoori, N Arefkhah, S Shahryari, M Mohseni, M Abbasi, J Noushadian   +7 more
doaj  

Therapeutic efficacy of butenafine nanomedicines in experimental cutaneous leishmaniasis [PDF]

, 2019
The production of ergosterol lipid, important for the Leishmania membrane homeostasis, involves different enzymes. This pathway can be blocked to azoles and allylamines drugs, such as the antifungal butenafine chloride. This drug was active (in vitro) against L. (L.) amazonensis and L.
Passero, Luiz Felipe D., Sousa, A. B., Jesus, J.A., Lalatsa, Katerina, Laurenti, M. D.   +4 more
openaire  

Experimental Cutaneous Leishmaniasis

Journal of Investigative Dermatology, 1963
Zuckerman, Avivah, Sagher, Felix
openaire   +1 more source

Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. [PDF]

, 1989
We purified poly(A)+ mRNA from the spleen and lymph nodes at designated times after infection with Leishmania major in genetically susceptible BALB/c and resistant C57BL/6 mice.
Coffman, RL, Heinzel, FP, Holaday, BJ, Locksley, RM, Sadick, MD   +4 more
core